Lyell Immunopharma, Inc.
LYEL
$10.76
-$0.21-1.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.11% | -4.41% | -53.08% | -99.87% | -99.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.11% | -4.41% | -53.08% | -99.87% | -99.89% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 11.11% | -4.41% | -53.08% | -99.87% | -99.89% |
| SG&A Expenses | -7.90% | -14.06% | -22.31% | -36.77% | -40.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -42.42% | -49.57% | -31.64% | -15.57% | 20.19% |
| Total Operating Expenses | -6.03% | -8.23% | -11.07% | -13.58% | -12.75% |
| Operating Income | 6.03% | 8.23% | 11.05% | -7.11% | -7.40% |
| Income Before Tax | -57.61% | -46.50% | -46.18% | -7.31% | -0.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.61% | -46.50% | -46.18% | -7.31% | -0.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.61% | -46.50% | -46.18% | -7.31% | -0.36% |
| EBIT | 6.03% | 8.23% | 11.05% | -7.11% | -7.40% |
| EBITDA | 4.77% | 7.99% | 11.76% | -8.22% | -8.00% |
| EPS Basic | -42.30% | -34.24% | -36.58% | -5.48% | 1.25% |
| Normalized Basic EPS | 13.35% | 14.25% | 15.25% | -6.53% | -2.47% |
| EPS Diluted | -42.30% | -34.24% | -36.58% | -5.48% | 1.25% |
| Normalized Diluted EPS | 13.35% | 14.25% | 15.25% | -6.53% | -2.47% |
| Average Basic Shares Outstanding | 11.19% | 7.75% | 4.18% | 1.82% | 1.62% |
| Average Diluted Shares Outstanding | 11.19% | 7.75% | 4.18% | 1.82% | 1.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |